SeaStar Medical reports Q3 revenue of $67,500 from first commercial sales of QUELIMMUNE; net loss narrows to $4.5M

SeaStar Medical Holding Corp

2024-Q3 EPS reported -$6.10 revenue$68,000

First commercial revenue of $67,500 from direct QUELIMMUNE shipments to hospital customer; no revenue in Q3 2023.
Net loss $4.5M ($1.10/share) vs $7.2M ($9.02/share) in Q3 2023; cash $2.1M as of Sep 30.
Eliminated all $9M+ long-term debt during 2024; no long-term debt outstanding.
FDA granted Breakthrough Device Designation for SCD in chronic dialysis (4th designation).
NEUTRALIZE-AKI adult trial: 59 subjects enrolled, record October enrollment; 12 clinical sites.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.